Flow cytometry and the study of cerebrospinal fluid in leukaemic patients: additional facts

Abellán, Pascual Fernández; Sen, Ma. Luz De La; Sánchez, B.A. Burgos; Rivas, C; Calatayud, R

doi:10.1046/j.1365-2141.2002.3317_1.x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Rituximab In Autoimmune Diseases1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2003

2011

Publication Types

Select...

Article2

Book1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Restoration of erythropoiesis has also been observed in refractory cases of pure red cell aplasia after treatment with rituximab [20,25,26]. Observed responses were of a similar rapidity of onset to that seen in the patients with ITP.…”

Section: Rituximab In Autoimmune Diseasesmentioning

confidence: 71%

Untitled

2003

View full text Add to dashboard Cite

The CD20 cell marker appears early in the process of B cell development. In this review we focus on the results of attempts to utilize B cell depletion based on the use of a chimeric monoclonal antibody (MAb) specific for human CD20, rituximab, for the treatment of patients with autoimmune diseases. In 1997, rituximab was approved for the treatment of low-grade B cell non-Hodgkin's lymphoma. Following these encouraging results, rituximab started to be used experimentally in other diseases presumed to be due to B cell pathology. The first autoimmune disease to be treated effectively was chronic idiopathic thrombocytopaenia. More recent success has been demonstrated in patients with rheumatoid arthritis and systemic lupus erythematosus.

show abstract

Section: Rituximab In Autoimmune Diseasesmentioning

confidence: 71%